Event Title
The Use of the Levonorgestrel-Intrauterine System (LNG-IUS) in the Treatment of Heavy MenstrualBleeding in Adolescents with Hemostatic Conditions
Location
Science Center A255
Start Date
10-28-2016 3:30 PM
End Date
10-28-2016 4:50 PM
Research Program
Summer Undergraduate Research Fellowship at Cincinnati Children's Hospital Medical Center
Abstract
Background: Adolescents with bleeding disorders (BD) or those that use anticoagulants are at a higher risk of heavy menstrual bleeding (HMB), which can result in a decreased quality of life. We aimed to assess the efficacy of the LNG-IUS in management of HMB in adolescents with hemostatic conditions and compare results to those in patients using combined oral contraceptive (COC) pills. Methods: A retrospective chart review was conducted of 1,597 patients who presented to our clinic for menstrual management. 62 patients were included that reported HMB, had been diagnosed with a BD or were using anticoagulants, had initiated either COC or LNG-IUS with our clinic, and followed up for at least 1 year. Results: At 1 year 71.4% of COC users reported bleeding improvement and 53.6% required a change in their medical management. 82.6% of LNG-IUS BD patients reported improvement and 21.7% required a change. 100% of LNG-IUS anticoagulant patients reported improvement and 0% required a change. There were no significant differences between hematocrit and hemoglobin levels for the COC BD and LNG-IUS BD groups, and both had a significant (P=0.01) increase when comparing the initial values to those at 1 year. Conclusions: Our pilot study supports the use of the LNG-IUS as a viable management method for adolescents with hemostatic conditions and HMB. A trend for a higher frequency of bleeding improvement was found among LNG-IUS users as compared to COC users. LNG-IUS users required fewer changes in medical management to sustain their improved bleeding symptoms.
Recommended Citation
Jewell, Tess, "The Use of the Levonorgestrel-Intrauterine System (LNG-IUS) in the Treatment of Heavy MenstrualBleeding in Adolescents with Hemostatic Conditions" (2016). Celebration of Undergraduate Research. 4.
https://digitalcommons.oberlin.edu/cour/2016/panel_08/4
Major
Gender, Sexuality, & Feminist Studies; Biology
Project Mentor(s)
Gylynthia Trotman, Department of Pediatric and Adolescent Gynecology, Cincinnati Children's Hospital Medical Center
Document Type
Presentation
The Use of the Levonorgestrel-Intrauterine System (LNG-IUS) in the Treatment of Heavy MenstrualBleeding in Adolescents with Hemostatic Conditions
Science Center A255
Background: Adolescents with bleeding disorders (BD) or those that use anticoagulants are at a higher risk of heavy menstrual bleeding (HMB), which can result in a decreased quality of life. We aimed to assess the efficacy of the LNG-IUS in management of HMB in adolescents with hemostatic conditions and compare results to those in patients using combined oral contraceptive (COC) pills. Methods: A retrospective chart review was conducted of 1,597 patients who presented to our clinic for menstrual management. 62 patients were included that reported HMB, had been diagnosed with a BD or were using anticoagulants, had initiated either COC or LNG-IUS with our clinic, and followed up for at least 1 year. Results: At 1 year 71.4% of COC users reported bleeding improvement and 53.6% required a change in their medical management. 82.6% of LNG-IUS BD patients reported improvement and 21.7% required a change. 100% of LNG-IUS anticoagulant patients reported improvement and 0% required a change. There were no significant differences between hematocrit and hemoglobin levels for the COC BD and LNG-IUS BD groups, and both had a significant (P=0.01) increase when comparing the initial values to those at 1 year. Conclusions: Our pilot study supports the use of the LNG-IUS as a viable management method for adolescents with hemostatic conditions and HMB. A trend for a higher frequency of bleeding improvement was found among LNG-IUS users as compared to COC users. LNG-IUS users required fewer changes in medical management to sustain their improved bleeding symptoms.
Notes
Session II, Panel 8 - Disorders & Development